|[July 01, 2014]
First Licensing Deals for Stem Cell Company Accellta
HAIFA, Israel --(Business Wire)--
First licensing deals for stem cell company Accellta- this month the
company announced that it granted worldwide, non-exclusive rights to
Miltenyi Biotec to use one of Accellta's patents in manufacturing and
commercialization of Miltenyi Biotec's proprietary medium for stem cell
cultivation. Miltenyi Biotec is active worldwide and is one of the
innovative leaders in products, services and clinical applications for
biomedical research and cell therapy.
Several months ago, Accellta granted a similar license to Japanese
nutrition and health giant, Ajinomoto. The non-exclusive license
includes manufacturing and marketing rights of the medium in Japan, for
both research and commercial applications. Ajinomoto has operations in
26 countries and encompasses a wide range of food and nutrition
products, amino acids, chemicals and pharmaceuticals, with annual
revenues exceeding USD 11 billion.
Accellta offers a range of revolutionary solutions for better
affordability and quality of stem cell culturing and for developing
disease models. The company was established in November 2012 by the
Technion and AMIT (the Alfred Mann Institute at the Technion); its
unique solutions are the result of over 15 years of pioneering research
and development at the Stem Cell Center in the Rappaport Faculty of
Medicine at the Technion- Israel Institute of Technology.
"The licensing deals leverage Accellta's intellectual property and allow
us to offer our unique solutions to stem cell scientists and researchers
worldwide, the number of which is estimated at over 100,000," says
Accellta Chairman, Dr. Zeev Gilkis. "We believe these deals pave the way
for more collaborations with the bomedical industry."
Since it was established, Accellta invested in creating strategic
business collaborations and building physical infrastructure for
clinical grade cell manufacturing. Recently it completed the
construction of a state-of-the-art manufacturing facility, which will be
used for industrial scale manufacturing of clinical-grade stem cells.
The complex, which will serve the emerging regenerative therapy
industry, is located in Haifa, Israel and includes 550 sqm of clean
rooms, QC laboratories, R&D laboratories and offices.
According to Dr. Michal Amit, one of the world pioneers in stem cell
research and Accellta's R&D manager, "The new manufacturing facility,
together with Accellta's innovative solutions, allow both stem cell
companies and research labs to culture higher quality cells in a faster,
more uniform, and much more cost-effective manner."
Among Accellta's proprietary solutions: MAXELLS- a proprietary
technology for cost-effective industrialization of stem cell
manufacturing. Maxells uses suspension culturing and delivers
unparalleled scalability and quality; SINGLES- a breakthrough technology
for simple and effective culturing of stem cells as single-cells in
suspension, which serves as a platform for genetic manipulation and
provides enhanced uniformity and purity. In addition Accellta markets
several stem cell lines and unique feeder cells.
Nowadays Accellta is focused on creating strategic partnerships with
Biopharma companies and Stem Cell companies for developing economic
manufacturing processes for cell products and for developing model
systems for new drug screening and testing. In the future the company
will also enter the market of regenerative medicine and develop
therapies for currently incurable diseases.
Accellta develops, manufactures and markets a range of revolutionary
solutions for better affordability and quality of stem cell culturing.
Accellta's technologies are the result of over 15 years of pioneering
research and development at the Stem Cell Center in the Technion's
Rappaport Faculty of Medicine. Accellta is a subsidiary of the Alfred
Mann Institute at the Technion (AMIT) and operates a state-of-the-art
manufacturing facility, laboratories and offices in Haifa, Israel. www.accellta.com
AMIT- Alfred Mann Institute at the Technion is the Technion hub for
biomedical innovation, active since 2006, it supports the development
and commercialization of exceptional bio-medical technologies conceived
by Technion researchers. The institute is chaired and funded by American
Billionaire and Philanthropist Dr. Alfred E. Mann. AMIT owns three
startup companies- Accellta, Sealantis and Sanoculis. www.amitechnion.com
[ Back To TMCnet.com's Homepage ]